BCAX Stock: Insider Activity, Filings & Research

Bicara Therapeutics Inc. Common Stock (BCAX) — Drillr’s hub for BCAX insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, BCAX insiders filed 0 open-market buys and 17 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$2.5M

Insider trades by month Buys Sells

Dec

Jan

Feb

Mar

Apr

May

Context3-month price +7.9%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 26, 2026	Hyep Ivanofficer: Chief Financial Officer	Sell	9,200	$20.42
May 26, 2026	Hyep Ivanofficer: Chief Financial Officer	Option	9,200	$3.79
May 20, 2026	Mazumdar Clairedirector, officer: Chief Executive Officer	Sell	12,022	$19.96
May 20, 2026	Mazumdar Clairedirector, officer: Chief Executive Officer	Sell	2,978	$20.35
May 20, 2026	Mazumdar Clairedirector, officer: Chief Executive Officer	Option	15,000	$3.79
May 18, 2026	Cohlhepp Ryandirector, officer: President and COO	Sell	8,000	$20.29
May 18, 2026	Cohlhepp Ryandirector, officer: President and COO	Sell	4,500	$20.29
May 18, 2026	Cohlhepp Ryandirector, officer: President and COO	Option	8,000	$3.79
May 12, 2026	Schelman Williamofficer: Chief Medical Officer	Grant	85,000	$22.58
Apr 28, 2026	Raben Davidofficer: Chief Medical Officer	Sell	5,500	$22.88
Apr 28, 2026	Raben Davidofficer: Chief Medical Officer	Option	5,500	$3.79
Apr 22, 2026	Hyep Ivanofficer: Chief Financial Officer	Option	9,200	$3.79
Apr 22, 2026	Hyep Ivanofficer: Chief Financial Officer	Sell	9,200	$23.00
Apr 20, 2026	Mazumdar Clairedirector, officer: Chief Executive Officer	Option	7,454	$3.79
Apr 20, 2026	Mazumdar Clairedirector, officer: Chief Executive Officer	Option	7,080	$5.45

Source: BCAX SEC Form 4 filings, latest May 26, 2026. For informational purposes only — not investment advice.

Overview

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Boston, Massachusetts. The company operates as a subsidiary of Biocon Limited, a major Indian biopharmaceutical company. Bicara focuses on developing innovative bifunctional antibody therapies specifically designed to treat solid tumors, representing a novel approach in cancer treatment that combines two therapeutic mechanisms into a single drug molecule.

Business

Bicara Therapeutics operates in the biotechnology sector, specifically within the oncology therapeutics space. The company is developing what are known as bifunctional antibodies - sophisticated drug molecules that can simultaneously target two different biological pathways involved in cancer progression. The company's lead and currently only disclosed program is ficerafusp alfa, a bifunctional antibody that represents a novel approach to cancer treatment. This drug combines two distinct therapeutic components: an antibody that targets the epidermal growth factor receptor (EGFR) - a protein commonly overexpressed in many solid tumors - with a domain that binds to transforming growth factor beta (TGF-β), a signaling molecule that tumors often use to suppress the immune system and promote their own growth. To understand this approach, it's helpful to know that traditional cancer treatments typically target one pathway at a time. EGFR inhibitors block signals that tell cancer cells to grow and multiply, while TGF-β inhibitors help restore the body's immune response against tumors. By combining both mechanisms in a single molecule, ficerafusp alfa aims to attack cancer on multiple fronts simultaneously, potentially improving treatment effectiveness while reducing the complexity of combination therapies. The biotechnology industry in which Bicara operates is characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory hurdles. Companies in this space typically spend years developing drugs through preclinical research, followed by multiple phases of human clinical trials before seeking regulatory approval. Success rates are relatively low, but successful drugs can generate substantial revenues due to patent protection and the critical nature of cancer treatments.

Revenue model

As a clinical-stage biopharmaceutical company, Bicara Therapeutics currently generates no revenue from product sales, as evidenced by zero reported revenues across all financial periods. The company operates on a research and development model typical of early-stage biotech companies, funding its operations through equity financing and investment from its parent company, Biocon Limited. The company's future revenue model will depend on successfully advancing ficerafusp alfa through clinical trials and ultimately achieving regulatory approval. Once approved, biotechnology companies typically generate revenue through several mechanisms: direct product sales to hospitals and healthcare systems, licensing agreements with larger pharmaceutical companies for commercialization rights, or partnership deals that provide upfront payments and milestone-based royalties. Several factors could significantly impact Bicara's future profitability margins. Positive clinical trial results demonstrating superior efficacy or safety compared to existing treatments would strengthen pricing power and market adoption. Conversely, clinical setbacks, regulatory delays, or competitive developments in the EGFR or TGF-β inhibitor space could negatively impact the commercial potential. The bifunctional antibody approach itself represents both an opportunity and a risk - while it could differentiate ficerafusp alfa in the market, the complexity of manufacturing such molecules typically results in higher production costs compared to traditional monoclonal antibodies. The company's current financial model relies heavily on external funding to support ongoing research and development activities, with operating cash flow consistently negative as the company invests in advancing its clinical programs. The substantial cash position provides runway for continued operations, but the company will need to demonstrate clinical progress to maintain investor confidence and secure additional funding as needed.

Competitive moat

Bicara Therapeutics currently operates with a relatively narrow competitive moat, typical of early-stage biotechnology companies. The company's primary potential competitive advantage lies in its bifunctional antibody platform and the specific combination of EGFR and TGF-β targeting in ficerafusp alfa. This approach represents intellectual property that could provide exclusivity if the drug proves successful in clinical trials. However, the strength of this moat remains unproven and faces several challenges. The biotechnology industry is highly competitive, with numerous large pharmaceutical companies and specialized biotech firms developing various approaches to cancer treatment. Both EGFR inhibitors and TGF-β pathway modulators are active areas of research, meaning Bicara faces potential competition from companies developing alternative approaches to target these same pathways. The company's association with Biocon Limited provides some strategic advantages, including access to manufacturing capabilities and regulatory expertise, particularly in global markets. Biocon's established presence in the biopharmaceutical industry could facilitate future commercialization efforts and provide financial backing during development phases. The most significant threat to Bicara's competitive position comes from the inherent risks of clinical-stage drug development. If ficerafusp alfa fails to demonstrate sufficient efficacy or safety in clinical trials, the company's entire value proposition could be undermined. Additionally, larger pharmaceutical companies with more diverse pipelines and greater financial resources could potentially develop competing bifunctional approaches or superior combination therapies that address the same cancer treatment challenges. The regulatory environment also presents both opportunities and risks. While successful regulatory approval would provide patent protection and market exclusivity, the lengthy and uncertain approval process means that competitive dynamics could shift significantly before ficerafusp alfa reaches the market.

Risks & safety

Bicara Therapeutics maintains a strong financial position with substantial margin of safety from a liquidity perspective, though faces typical biotech operational risks. • Cash Position: Strong cash reserves of $462 million as of Q1 2025, providing significant operational runway • Burn Rate: Quarterly cash burn of approximately $28-30 million, suggesting roughly 4-5 years of funding at current spending levels • Debt Level: Minimal debt with debt-to-equity ratio of 0.0013, indicating very low financial leverage • Current Ratio: Exceptionally strong at 24.6x, demonstrating excellent short-term liquidity • Solvency Risk: Low near-term solvency risk given substantial cash position relative to current burn rate • Valuation Metrics: Currently loss-making with negative earnings, making traditional valuation metrics less meaningful; trading at 1.5x book value • Revenue Risk: Zero current revenue with all value dependent on successful clinical development and regulatory approval • Other Considerations: Clinical-stage risk remains the primary concern, with company value entirely dependent on ficerafusp alfa's clinical success; strong parent company backing through Biocon Limited provides additional financial stability.

Recent development

Based on the available financial data, Bicara Therapeutics has been primarily focused on advancing its lead program ficerafusp alfa through clinical development. The company's operational expenses have increased over recent quarters, suggesting intensified research and development activities, likely related to progressing clinical trials. The most significant development appears to be the company's substantial cash position improvement, with cash and short-term investments increasing from approximately $4 million at the end of 2022 to nearly $490 million by the end of 2024. This dramatic increase suggests the company completed a major financing round, likely in preparation for advancing ficerafusp alfa through more expensive later-stage clinical trials. The company's quarterly burn rate has stabilized in the $28-30 million range through recent quarters, indicating a consistent level of research and development investment. This spending pattern suggests ongoing clinical trial activities and preparation for potential expansion of the clinical program. The financial structure has also evolved significantly, with the company moving from a negative equity position in 2022-2023 to a strong positive equity position by 2024, reflecting both the major capital infusion and the resolution of previous financial obligations. This transformation positions the company with the financial resources necessary to execute on its clinical development strategy for ficerafusp alfa.

BCAX company profile · for informational purposes only — not investment advice.

Track BCAX with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free